Recent advances in ocular drug delivery

References

• Stjernschantz J, Astin M. (1993). Anatomy and physiology of the eye, physiological aspects of ocular drug therapy. In: Edman P, editor. Biopharmaceutics in Ocular Drug Delivery. Boca Raton: CRC Press, 1–25.
   Google Scholar
• Robinson JC. (2003). Ocular anatomy and physiology relevant to ocular drug delivery. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. New York: Etats-Unis, 29–57.
   Google Scholar
• Shell JW. (1982). Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol, 26:207–218.
   PubMed Web of Science ®Google Scholar
• Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. (2004). Cationic vectors in ocular drug delivery. J Drug Target, 12:623–633.
   PubMed Web of Science ®Google Scholar
• Janoria KG, Hariharan S, Dasari CR, Mitra AK. (2007). Recent patents and advances in ophthalmic drug delivery. Recent Pat Drug Deliv Formul, 1:161–170.
   PubMedGoogle Scholar
• Sirbat D, Marchal-Heussler L, Hoffman M, Maincent P. (2000). [Ways to improve ocular bioavailability for topical applications]. J Fr Ophtalmol, 23:505–9; quiz 523.
   PubMed Web of Science ®Google Scholar
• Kompella UB, Kadam RS, Lee VH. (2010). Recent advances in ophthalmic drug delivery. Ther Deliv, 1:435–456.
   PubMedGoogle Scholar
• Lallemand F, Perottet P, Felt-Baeyens O, Kloeti W, Philippoz F, Marfurt J et al. (2005). A water-soluble prodrug of cyclosporine A for ocular application: A stability study. Eur J Pharm Sci, 26:124–129.
   PubMed Web of Science ®Google Scholar
• Tirucherai GS, Dias C, Mitra AK. (2002). Corneal permeation of ganciclovir: Mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. J Ocul Pharmacol Ther, 18:535–548.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kanwar M. (2002). Ocular preparations: The formulation approach. Drug Dev Ind Pharm, 28:473–493.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Chhabra S, Aggarwal D. (2004). Role of cyclodextrins in ophthalmics. Curr Drug Deliv, 1:351–360.
   PubMedGoogle Scholar
• Loftsson T, Stefánsson E. (2002). Cyclodextrins in eye drop formulations: Enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand, 80:144–150.
   PubMedGoogle Scholar
• Saari KM, Nelimarkka L, Ahola V, Loftsson T, Stefánsson E. (2006). Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation. Graefes Arch Clin Exp Ophthalmol, 244:620–626.
   PubMed Web of Science ®Google Scholar
• Sigurdsson HH, Konráethsdóttir F, Loftsson T, Stefánsson E. (2007). Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand, 85:598–602.
   PubMedGoogle Scholar
• Singh SK, Bandyopadhyay P, Hassan S, inventors. (2004). Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride. US patent 0019012.
   Google Scholar
• Loftsson T, Stefansson E, inventors. (2007). Cyclodextrin nanotechnology for ophthalmic drug delivery. US patent 0020336.
   Google Scholar
• Ito Y, Nagai N, Shimomura Y. (2010). Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-ß-cyclodextrin in rabbit. Biol Pharm Bull, 33:1574–1578.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Igarashi Y, Nagano T, Nishida K, Nakamura J. (1995). Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic β-blockers. Pharm Res, 12:1146–1150.
   PubMed Web of Science ®Google Scholar
• Nanjawade BK, Manvi FV, Manjappa AS. (2007). In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release, 122:119–134.
   PubMed Web of Science ®Google Scholar
• Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. (1998). Ophthalmic drug delivery systems–recent advances. Prog Retin Eye Res, 17:33–58.
   PubMed Web of Science ®Google Scholar
• Ludwig A. (2005). The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev, 57:1595–1639.
   PubMed Web of Science ®Google Scholar
• Laroche L, Arrata M, Brasseur G, Lagoutte F, Le Mer Y, Lumbroso P et al. (1991). [Treatment of dry eye syndrome with lacrimal gel: A randomized multicenter study]. J Fr Ophtalmol, 14:321–326.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Murphy PJ, Boulton M. (2006). Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graefes Arch Clin Exp Ophthalmol, 244:109–112.
   PubMed Web of Science ®Google Scholar
• Khamar BM, inventor. (2001). Ophthalmic formulation comprising a β blocker and carbopol. EP patent 1137407.
   Google Scholar
• Lu GW. (2010). Recent advances in developing ophthalmic formulations: A patent review. Recent Pat Drug Deliv Formul, 4:49–57.
   PubMedGoogle Scholar
• Gurtler F, Gurny R. (1995). Patent literature review of ophthalmic inserts. Drug Dev Ind Pharm, 21:1–18.
   Web of Science ®Google Scholar
• Escobar-Chávez JJ, López-Cervantes M, Naïk A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar A. (2006). Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. J Pharm Pharm Sci, 9:339–358.
   PubMed Web of Science ®Google Scholar
• El-Kamel AH. (2002). In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm, 241:47–55.
   PubMed Web of Science ®Google Scholar
• Shastri D, Patel L, Parikh R. (2010). Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery. J Young Pharm, 2:116–120.
   PubMedGoogle Scholar
• Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. (2001). In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm, 229:29–36.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Murphy PJ, Boulton M. (2008). Carbomer and sodium hyaluronate eyedrops for moderate dry eye treatment. Optom Vis Sci, 85:750–757.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Ramchandraiah S, Jain CP, Jain SK. (1992). Polymeric pseudolatices bearing pilocarpine for controlled ocular delivery. J Microencapsul, 9:347–355.
   PubMed Web of Science ®Google Scholar
• Maurice DM, Srinivas SP. (1992). Use of fluorometry in assessing the efficacy of a cation-sensitive gel as an ophthalmic vehicle: Comparison with scintigraphy. J Pharm Sci, 81:615–619.
   PubMed Web of Science ®Google Scholar
• Carlfors J, Edsman K, Petersson R, Jörnving K. (1998). Rheological evaluation of Gelrite in situ gels for ophthalmic use. Eur J Pharm Sci, 6:113–119.
   PubMed Web of Science ®Google Scholar
• Balasubramaniam J, Pandit JK. (2003). Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv, 10:185–191.
   PubMed Web of Science ®Google Scholar
• El-Kamel A, Al-Dosari H, Al-Jenoobi F. (2006). Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv, 13:55–59.
   PubMed Web of Science ®Google Scholar
• Sultana Y, Aqil M, Ali A, Zafar S. (2006). Evaluation of carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol, 11:313–319.
   PubMed Web of Science ®Google Scholar
• Mohan EC. (2009). Preparation and evaluation of in-situ-gels for ocular drug delivery. J Pharm Res, 2:1089–1094.
   Google Scholar
• Séchoy O, Tissié G, Sébastian C, Maurin F, Driot JY, Trinquand C. (2000). A new long acting ophthalmic formulation of carteolol containing alginic acid. Int J Pharm, 207:109–116.
   PubMed Web of Science ®Google Scholar
• Demailly P, Allaire C, Trinquand C; Once-daily Carteolol Study Group. (2001). Ocular hypotensive efficacy and safety of once daily carteolol alginate. Br J Ophthalmol, 85:921–924.
   PubMed Web of Science ®Google Scholar
• Trinquand C, Romanet JP, Nordmann JP, Allaire C; Groupe d’étude. (2003). [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. J Fr Ophtalmol, 26:131–136.
   PubMed Web of Science ®Google Scholar
• Lang JC, Keister JC, Missel PJT, Stancioff DJ, inventors. (1995). Use of carrageenans in topical ophthalmic compositions. US patent 5403841.
   Google Scholar
• Srividya B, Cardoza RM, Amin PD. (2001). Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release, 73:205–211.
   PubMed Web of Science ®Google Scholar
• Lin HR, Sung KC, inventors. (2003). Ophthalmic drug delivery formulations and method for preparing the same. US patent 6511660.
   Google Scholar
• Liu Z, Pan W, Nie S, Zhang L, Yang X, Li J. (2005). Preparation and evaluation of sustained ophthalmic gel of enoxacin. Drug Dev Ind Pharm, 31:969–975.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li J, Nie S, Liu H, Ding P, Pan W. (2006). Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm, 315:12–17.
   PubMed Web of Science ®Google Scholar
• Gupta H, Jain S, Mathur R, Mishra P, Mishra AK, Velpandian T. (2007). Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv, 14:507–515.
   PubMed Web of Science ®Google Scholar
• Singh V, Bushetti SS, Appala R, Shareef A, Imam SS, Singh M. (2010). Stimuli-sensitive hydrogels: A novel ophthalmic drug delivery system. Indian J Ophthalmol, 58:477–481.
   PubMed Web of Science ®Google Scholar
• Schoenwald RD. (1993). Pharmacokinetics in ocular drug delivery. In: Edman P, editor. Biopharmaceutics of Ocular Drug Delivery. Mitra AK, 159–193.
   Google Scholar
• Pietzyk B, Henschke K. (2000). Degradation of phosphatidylcholine in liposomes containing carboplatin in dependence on composition and storage conditions. Int J Pharm, 196:215–218.
   PubMed Web of Science ®Google Scholar
• Hathout RM, Mansour S, Mortada ND, Guinedi AS. (2007). Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies. AAPS PharmSciTech, 8:1.
   PubMed Web of Science ®Google Scholar
• Shen Y, Tu J. (2007). Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS J, 9:E371–E377.
   PubMed Web of Science ®Google Scholar
• Mehanna MM, Elmaradny HA, Samaha MW. (2009). Mucoadhesive liposomes as ocular delivery system: Physical, microbiological, and in vivo assessment. Drug Dev Ind Pharm, 36:108–118.
   Web of Science ®Google Scholar
• Habib FS, Fouad EA, Abdel-Rhaman MS, Fathalla D. (2010). Liposomes as an ocular delivery system of fluconazole: In-vitro studies. Acta Ophthalmol, 88:901–904.
   PubMed Web of Science ®Google Scholar
• Budai L, Hajdú M, Budai M, Gróf P, Béni S, Noszál B et al. (2007). Gels and liposomes in optimized ocular drug delivery: Studies on ciprofloxacin formulations. Int J Pharm, 343:34–40.
   PubMed Web of Science ®Google Scholar
• Hosny KM. (2009). Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin. AAPS PharmSciTech, 10:1336–1342.
   PubMed Web of Science ®Google Scholar
• Hosny KM. (2010). Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSciTech, 11:241–246.
   PubMed Web of Science ®Google Scholar
• Zhang J, Guan P, Wang T, Chang D, Jiang T, Wang S. (2009). Freeze-dried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation. J Pharm Pharmacol, 61:1171–1178.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang S. (2009). Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: Tolerance, precorneal retention and anti-cataract effect. Int J Pharm, 372:66–75.
   PubMed Web of Science ®Google Scholar
• Aggarwal D, Kaur IP. (2005). Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm, 290:155–159.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Aggarwal D, Singh H, Kakkar S. (2010). Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. Graefes Arch Clin Exp Ophthalmol, 248:1467–1472.
   PubMed Web of Science ®Google Scholar
• Guinedi AS, Mortada ND, Mansour S, Hathout RM. (2005). Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm, 306:71–82.
   PubMed Web of Science ®Google Scholar
• Aggarwal D, Pal D, Mitra AK, Kaur IP. (2007). Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm, 338:21–26.
   PubMed Web of Science ®Google Scholar
• Abdelbary G, El-Gendy N. (2008). Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech, 9:740–747.
   PubMed Web of Science ®Google Scholar
• Garg G, Saraf S, Saraf S. (2007). Cubosomes: An overview. Biol Pharm Bull, 30:350–353.
   PubMed Web of Science ®Google Scholar
• Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X et al. (2010). Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm, 396:179–187.
   PubMed Web of Science ®Google Scholar
• Han S, Shen JQ, Gan Y, Geng HM, Zhang XX, Zhu CL et al. (2010). Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin, 31:990–998.
   PubMed Web of Science ®Google Scholar
• Klang SH, Siganos CS, Benita S, Frucht-Pery J. (1999). Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn. J Control Release, 57:19–27.
   PubMed Web of Science ®Google Scholar
• Abdulrazik M, Tamilvanan S, Khoury K, Benita S. (2001). Ocular delivery of cyclosporin A. II. Effect of submicron emulsion’s surface charge on ocular distribution of topical cyclosporin A. Paris: Editions de santé.
   Google Scholar
• Benita S, Lambert G, inventors. (2003). Method and composition for dry eye treatment. US patent 0108626.
   Google Scholar
• Bague S, Betty P, Sebastien GJ, >inventors. (2006). Oil in water type emulsion with low concentration of cationic agent and positive zeta potentiel. US patent 0100288.
   Google Scholar
• Klang S, Abdulrazik M, Benita S. (2000). Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol, 5:521–532.
   PubMed Web of Science ®Google Scholar
• Gan L, Gan Y, Zhu C, Zhang X, Zhu J. (2009). Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: In vitro and in vivo results. Int J Pharm, 365:143–149.
   PubMed Web of Science ®Google Scholar
• Fialho SL, da Silva-Cunha A. (2004). New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol, 32:626–632.
   PubMed Web of Science ®Google Scholar
• Ammar HO, Salama HA, Ghorab M, Mahmoud AA. (2009). Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech, 10:808–819.
   PubMed Web of Science ®Google Scholar
• Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. (1991). [Nanocapsules of β-blocking agents: A new drug carrier in ophthalmology. Application to medical treatment of glaucoma in rabbits]. J Fr Ophtalmol, 14:371–375.
   PubMed Web of Science ®Google Scholar
• Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. (1993). Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res, 10:386–390.
   PubMed Web of Science ®Google Scholar
• De Campos AM, Sánchez A, Alonso MJ. (2001). Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm, 224:159–168.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. (2002). Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 23:3247–3255.
   PubMed Web of Science ®Google Scholar
• Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G et al. (2003). Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res, 20:584–590.
   PubMed Web of Science ®Google Scholar
• de Campos AM, Diebold Y, Carvalho EL, Sánchez A, Alonso MJ. (2004). Chitosan nanoparticles as new ocular drug delivery systems: In vitro stability, in vivo fate, and cellular toxicity. Pharm Res, 21:803–810.
   PubMed Web of Science ®Google Scholar
• Enriquez de Salamanca A, Diebold Y, Calonge M, Garcia-Vazquez C, Callejo S, Vila A et al. (2006). Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci, 47:1416–1425.
   PubMed Web of Science ®Google Scholar
• Vega E, Egea MA, Valls O, Espina M, García ML. (2006). Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J Pharm Sci, 95:2393–2405.
   PubMed Web of Science ®Google Scholar
• Kao HJ, Lin HR, Lo YL, Yu SP. (2006). Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles. J Pharm Pharmacol, 58:179–186.
   PubMed Web of Science ®Google Scholar
• Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. (2007). Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm, 340:126–133.
   PubMed Web of Science ®Google Scholar
• Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. (2008). Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm, 68:513–525.
   PubMed Web of Science ®Google Scholar
• Yenice I, Mocan MC, Palaska E, Bochot A, Bilensoy E, Vural I et al. (2008). Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. Exp Eye Res, 87:162–167.
   PubMed Web of Science ®Google Scholar
• Sakai T, Ishihara T, Higaki M, Akiyama G, Tsuneoka H. (2011). Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci, 52:1516–1521.
   PubMed Web of Science ®Google Scholar
• Ibrahim HK, El-Leithy IS, Makky AA. (2010). Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol Pharm, 7:576–585.
   PubMed Web of Science ®Google Scholar
• Uner M, Yener G. (2007). Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine, 2:289–300.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. (2002). Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm, 238:241–245.
   PubMed Web of Science ®Google Scholar
• Pierscionek BK, Li Y, Yasseen AA, Colhoun LM, Schachar RA, Chen W. (2010). Nanoceria have no genotoxic effect on human lens epithelial cells. Nanotechnology, 21:035102.
   Web of Science ®Google Scholar
• Chen J, Patil S, Seal S, McGinnis JF. (2008). Nanoceria particles prevent ROI-induced blindness. Adv Exp Med Biol, 613:53–59.
   PubMed Web of Science ®Google Scholar